bZIP transcription factors regulate conversion of nicotine to nornicotine and reduce levels of tobacco specific (TSNA) precursors

US12344853B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12344853-B2
Application numberUS-202017605506-A
CountryUS
Kind codeB2
Filing dateJun 5, 2020
Priority dateJun 5, 2019
Publication dateJul 1, 2025
Grant dateJul 1, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A method of decreasing conversion of nicotine to nornicotine is provided herein. The methods includes administering at least one basic region/leucine zipper (bZIP) type transcription factor inhibitor to an organism in need thereof. Also provided herein is a method of decreasing conversion of nicotine to nornicotine including mutating a bZIP type transcription factor binding site on a promoter of a nicotine N-demethylase (NND). Further provided herein is a method of decreasing conversion of nicotine to nornicotine including mutating a plant genome to knockout at least one bZIP type transcription factor.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of decreasing conversion of nicotine to nornicotine and/or a method of reducing levels of at least one tobacco specific (TSNA) precursor, the method comprising reducing the activity and/or expression of at least one basic region/leucine zipper (bZIP) type transcription factor in a tobacco plant, a part of a tobacco plant, a tobacco plant cell or cell culture, or a tobacco plant seed, wherein the bZIP transcription factor comprises an amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 1 or 3; an amino acid having the sequence of SEQ ID NO: 2, 4, 5, or 6; an amino acid sequence having at least 95% identity to the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 1 or 3 and which binds a promoter of a nicotine N-demethylase (NND) selected from the group consisting of CYP82E4v1, CYP82E5v2, and CYP82E10; an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2, 4, 5, or 6 and which binds a promoter of a nicotine N-demethylase (NND) selected from the group consisting of CYP82E4v1, CYP82E5v2, and CYP82E10; or combinations thereof. 2. The method of claim 1 , wherein the at least one bZIP transcription factor is selected from the group consisting of group C bZIP transcription factor, group S bZIP transcription factor, and combinations thereof. 3. The method of claim 1 , wherein the at least one bZIP transcription factor is selected from the group consisting of NtbZIP1a, NtbZIP1b, NtbZIP2a, NtbZIP2b, and combinations thereof. 4. The method of claim 1 , wherein the at least one bZIP transcription factor comprises an amino acid molecule having at least 97%, 98%, 99%, or 100% identity to an amino acid selected from the group consisting of the amino acid encoded by SEQ ID NO: 1; the amino acid of SEQ ID NO: 2; the amino acid encoded by SEQ ID NO: 3; the amino acid of SEQ ID NO: 4; the amino acid of SEQ ID NO: 5; and the amino acid of SEQ ID NO: 6. 5. The method of claim 1 , wherein the at least one bZIP transcription factor comprises NtbZIP1a and NtbZIP1b. 6. The method of claim 1 , wherein the at least one bZIP transcription factor comprises NtbZIP2a and NtbZIP2b. 7. The method of claim 1 , wherein the at least one bZIP transcription factor comprises NtbZIP1a, NtbZIP1b, NtbZIP2a, and NtbZIP2b. 8. The method of claim 1 , wherein the at least one bZIP transcription factor comprises: an amino acid molecule having at least 97%, 98%, 99%, or 100% identity to an amino acid selected from the group consisting of the amino acid encoded by SEQ ID NO: 1 and the amino acid of SEQ ID NO: 2; and an amino acid molecule having at least 97%, 98%, 99%, or 100% identity to an amino acid selected from the group consisting of the amino acid encoded by SEQ ID NO: 3 and the amino acid of SEQ ID NO: 4. 9. The method of claim 1 , wherein the at least one bZIP transcription factor comprises: an amino acid molecule having at least 97%, 98%, 99%, or 100% identity to the amino acid of SEQ ID NO: 5; and an amino acid molecule having at least 97%, 98%, 99%, or 100% identity to the amino acid of SEQ ID NO: 6. 10. The method of claim 1 , wherein the at least one bZIP transcription factor comprises: an amino acid molecule having at least 97%, 98%, 99%, or 100% identity to an amino acid selected from the group consisting of the amino acid encoded by SEQ ID NO: 1 and the amino acid of SEQ ID NO: 2; an amino acid molecule having at least 97%, 98%, 99%, or 100% identity to an amino acid selected from the group consisting of the amino acid encoded by SEQ ID NO: 3 and the amino acid of SEQ ID NO: 4; an amino acid molecule having at least 97%, 98%, 99%, or 100% identity to the amino acid of SEQ ID NO: 5; and/or an amino acid molecule having at least 97%, 98%, 99%, or 100% identity to the amino acid of SEQ ID NO: 6. 11. The method of claim 1 , wherein reducing the activity and/or expression of the at least one bZIP type transcription factor comprises: mutating the bZIP type transcription factor by providing a mutation in a binding site of the bZIP type transcription factor; mutating the binding site on a promoter of a nicotine N-demethylase (NND); using a bZIP type transcription factor inhibitor; or using a gene silencing technique. 12. The method of claim 11 , wherein the bZIP transcription factor inhibitor is selected from the group consisting of antisense oligonucleotides, miRNA, siRNA, locked nucleic acid (LNA) nucleotides, and combination thereof. 13. The method of claim 11 , wherein mutating the bZIP type transcription factor comprises mutating the binding site on a promoter of a nicotine N-demethylase (NND). 14. The method of claim 13 , wherein the NND is selected from the group consisting of CYP82E4v1, CYP82E5v2, and CYP82E10. 15. The method of claim 14 , wherein the NND is CYP82E4v1 and wherein the bZIP binding site on the promoter of CYP82E4v1 is an A/G box with a pre-mutated sequence of TACGTC. 16. The method of claim 15 , wherein the mutated binding site has the sequence TGCGTC. 17. The method of claim 16 , wherein the mutated binding site is formed by site-directed mutagenesis. 18. The method of claim 11 , wherein mutating the bZIP type transcription factor comprises mutating a plant genome to knockout at least one basic region/leucine zipper (bZIP) type transcription factor. 19. The method of claim 18 , wherein the at least one bZIP transcription factor is selected from the group consisting of group C bZIP transcription factor, group S bZIP transcription factor, and combinations thereof. 20. The method of claim 18 , wherein the at least one bZIP transcription factor is selected from the group consisting of NtbZIP1a, NtbZIP1b, NtbZIP2a, NtbZIP2b, and combinations thereof. 21. The method of claim 18 , wherein the at least one bZIP transcription factor comprises an amino acid sequence selected from the group consisting of: an amino acid molecule having at least 97%, 98%, 99%, or 100% identity to an amino acid selected from the group consisting of the amino acid encoded by SEQ ID NO: 1 and the amino acid of SEQ ID NO: 2; an amino acid molecule having at least 97%, 98%, 99%, or 100% identity to an amino acid selected from the group consisting of the amino acid encoded by SEQ ID NO: 3 and the amino acid of SEQ ID NO: 4; an amino acid molecule having at least 97%, 98%, 99%, or 100% identity to the amino acid of SEQ ID NO: 5; and an amino acid molecule having at least 97%, 98%, 99%, or 100% identity to the amino acid of SEQ ID NO: 6. 22. A tobacco cell culture or plant: comprising a plant cell comprising a nucleic acid molecule encoding a bZIP type transcription factor having at least one mutation, wherein the bZIP transcription factor comprises an amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 1 or 3; an amino acid having the sequence of SEQ ID NO: 2, 4, 5, or 6; or combinations thereof; wherein the tobacco cell culture or plant provides a decrease in conversion of nicotine to nornicotine and/or reduction in levels of at least one tobacco specific (TSNA) precursor of said culture or plant compared with that of an unmodified culture or plant. 23. A method of breeding a tobacco plant, the method comprising breeding the tobacco cell culture or plant of claim 22 . 24. A method of producing a tobacco industry product, the method comprising producing the tobacco cell culture or plant of claim 22 . 25. A method of grow

Assignees

Inventors

Classifications

  • Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS] · CPC title

  • C07K14/415Primary

    from plants · CPC title

  • Blending tobacco · CPC title

  • Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff (reconstituted tobacco products A24B3/14) · CPC title

  • in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12344853B2 cover?
A method of decreasing conversion of nicotine to nornicotine is provided herein. The methods includes administering at least one basic region/leucine zipper (bZIP) type transcription factor inhibitor to an organism in need thereof. Also provided herein is a method of decreasing conversion of nicotine to nornicotine including mutating a bZIP type transcription factor binding site on a promoter o…
Who is the assignee on this patent?
Univ Kentucky Res Found, Reynolds Tobacco Co R
What technology area does this patent fall under?
Primary CPC classification C07K14/415. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).